Aberdeen Group
MYOK

Aberdeen Group’s MyoKardia, Inc. Common Stock MYOK Stock Holding History

Aberdeen Group’s Portfolio MYOK Stock Details MYOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-41,902
Closed -$2.04M – 923
2018
Q1 		$2.04M Buy
+41,902
New +$2.18M ﹤0.01% 664
2017
Q4 		– Sell
-48,155
Closed -$2.06M – 802
2017
Q3 		$2.06M Buy
+48,155
New +$1.54M ﹤0.01% 645

Other funds holding MYOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Hillhouse Investment Management
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Aberdeen Group's MYOK Position: Q2 2018 in Review

Aberdeen Group sold out of MyoKardia, Inc. Common Stock (MYOK) in Q2 2018, closing a stake of 41,902 shares — an estimated $2.04M sold.

Aberdeen Group first reported a position in MYOK in Q3 2017 and held it in 2 quarters. The position peaked at $2.06M in Q3 2017. 121 funds tracked by Wall St. Rank hold MYOK as of Q2 2018.

  • Aberdeen Group reported no remaining MyoKardia, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Aberdeen Group sold 41,902 MyoKardia, Inc. Common Stock shares in Q2 2018, an estimated $2.04M.
  • Aberdeen Group first reported a position in MyoKardia, Inc. Common Stock in Q3 2017 and held it in 2 quarters.
  • Aberdeen Group's MyoKardia, Inc. Common Stock position peaked at $2.06M in Q3 2017.
  • 121 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q2 2018.

Based on Aberdeen Group's 13F filing for Q2 2018, filed 9 Aug 2018.